• Hunter Capital RTO 1 shareholders will vote at an extraordinary general meeting on acquiring ResoTher Pharma through newly issued shares.
• The transaction values ResoTher Pharma at approximately SEK 273 million versus SEK 60 million for the listed company.
• ResoTher Pharma shareholders would hold approximately 82% of the combined company; existing shareholders would retain approximately 18%.
• Shareholders will also vote on a reverse stock split and amendments to the articles of association.
• Completion would unlock a SEK 32 million convertible loan facility, bringing total transaction-related financing to approximately SEK 80 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hunter Capital RTO 1 AB (publ) published the original content used to generate this news brief via Cision (Ref. ID: 202610280430BITN____UKPR__SV_20261027-BIT-0878-0) on October 28, 2026, and is solely responsible for the information contained therein.